2. Academic Validation
  3. Safe and Highly Efficient Lipid-Pro-Dexamethasone Nanoparticles for mRNA Delivery and Base Editing

Safe and Highly Efficient Lipid-Pro-Dexamethasone Nanoparticles for mRNA Delivery and Base Editing

  • J Am Chem Soc. 2026 Mar 11;148(9):10225-10240. doi: 10.1021/jacs.6c01708.
Yan Zong 1,  Haiping Zhong 2 3,  Yuqing Wang 1,  Yi Lin 1,  Linxi Zhao 1,  Xiaoyu Wang 1,  Jianan Cai 2,  Haoyang Lin 2,  Yixi Xiao 1,  Tuo Wei 4,  Shutao Guo 2,  Qiang Cheng 1 5
Affiliations

Affiliations

  • 1 Department of Biomedical Engineering, College of Future Technology, Peking University, Beijing 100871, China.
  • 2 Key Laboratory of Functional Polymer Materials of Ministry of Education, State Key Laboratory of Medicinal Chemical Biology, Frontiers Science Center for New Organic Matter, College of Chemistry, Nankai University, Tianjin 300071, China.
  • 3 School of Biomedical Engineering, Guangzhou Medical University, Guangzhou 510260, China.
  • 4 State Key Laboratory of Organ Regeneration and Reconstruction, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China.
  • 5 Beijing Advanced Center of RNA Biology (BEACON), Peking University, Beijing 100871, China.
PMID: 41733506 DOI: 10.1021/jacs.6c01708
Abstract

The inherent immunogenicity of mRNA lipid nanoparticles (LNPs) poses a major challenge to their application in disease treatment. In this study, we developed a series of innovative dexamethasone (DEX) prodrug ionizable lipids (DPILs) to address the need for safe and effective mRNA delivery, leading to the establishment of the Safe and Highly Efficient Lipid-pro-dexamethasone (SHIELD) LNP platform. The lead formulation, DEX-SPM-CP10 SHIELD LNP, not only markedly decreased the levels of multiple proinflammatory cytokines but also achieved mRNA delivery efficiency comparable to that of the FDA-approved SM-102 LNP. Furthermore, the SHIELD platform demonstrated universality, as incorporating specific ratios of DPILs into various LNPs targeting different organs (such as the liver, lungs, spleen, and pancreas) led to notable reductions in inflammatory responses and enhancements in mRNA expression, highlighting its superiority over strategies that incorporate free DEX. Subsequently, we investigated its application in gene editing therapy by codelivering ABEmax mRNA and sgRNA to edit the EGFP reporter gene and endogenous PCSK9 gene, as well as in protein replacement therapy through multiple injections of mRNA-SHIELD LNPs. All of these results demonstrated excellent delivery efficacy with minimal immunogenicity, fully illustrating the therapeutic potential of this platform. Taken together, the SHIELD platform offers safe and efficient mRNA delivery and has the potential to expand the therapeutic applications of mRNA-based therapies.

Figures
Products